980 related articles for article (PubMed ID: 30790171)
1. Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement.
Rigopoulos AG; Ali M; Abate E; Torky AR; Matiakis M; Mammadov M; Melnyk H; Vogt A; de Vecchis R; Bigalke B; Wohlgemuth W; Mavrogeni S; Noutsias M
Heart Fail Rev; 2019 Jul; 24(4):521-533. PubMed ID: 30790171
[TBL] [Abstract][Full Text] [Related]
2. Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable.
Rubin J; Maurer MS
Annu Rev Med; 2020 Jan; 71():203-219. PubMed ID: 31986086
[TBL] [Abstract][Full Text] [Related]
3. A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.
Benbrahim M; Norman K; Sanchorawala V; Siddiqi OK; Hughes D
J Cardiovasc Pharmacol; 2021 May; 77(5):544-548. PubMed ID: 33657048
[TBL] [Abstract][Full Text] [Related]
4. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice.
Witteles RM; Bokhari S; Damy T; Elliott PM; Falk RH; Fine NM; Gospodinova M; Obici L; Rapezzi C; Garcia-Pavia P
JACC Heart Fail; 2019 Aug; 7(8):709-716. PubMed ID: 31302046
[TBL] [Abstract][Full Text] [Related]
5. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
6. Wild-Type Transthyretin Cardiac Amyloidosis: Novel Insights From Advanced Imaging.
Narotsky DL; Castano A; Weinsaft JW; Bokhari S; Maurer MS
Can J Cardiol; 2016 Sep; 32(9):1166.e1-1166.e10. PubMed ID: 27568874
[TBL] [Abstract][Full Text] [Related]
7. Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.
Yamamoto H; Hashimoto T; Kawamura S; Hiroe M; Yamashita T; Ando Y; Yokochi T
J Med Case Rep; 2018 Dec; 12(1):370. PubMed ID: 30553273
[TBL] [Abstract][Full Text] [Related]
8. Amyloid cardiomyopathy.
Kristen AV
Herz; 2020 May; 45(3):267-271. PubMed ID: 32107564
[TBL] [Abstract][Full Text] [Related]
9. Advances in the treatment of hereditary transthyretin amyloidosis: A review.
Gertz MA; Mauermann ML; Grogan M; Coelho T
Brain Behav; 2019 Sep; 9(9):e01371. PubMed ID: 31368669
[TBL] [Abstract][Full Text] [Related]
10. Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy.
Shintani Y; Okada A; Morita Y; Hamatani Y; Amano M; Takahama H; Amaki M; Hasegawa T; Ohta-Ogo K; Kanzaki H; Ishibashi-Ueda H; Yasuda S; Shimazaki C; Yoshinaga T; Yazaki M; Sekijima Y; Izumi C
ESC Heart Fail; 2019 Feb; 6(1):232-236. PubMed ID: 30478886
[TBL] [Abstract][Full Text] [Related]
11. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
Sekijima Y
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
[TBL] [Abstract][Full Text] [Related]
12. Noninvasive risk stratification of patients with transthyretin amyloidosis.
Kristen AV; Scherer K; Buss S; aus dem Siepen F; Haufe S; Bauer R; Hinderhofer K; Giannitsis E; Hardt S; Haberkorn U; Katus HA; Steen H
JACC Cardiovasc Imaging; 2014 May; 7(5):502-10. PubMed ID: 24726252
[TBL] [Abstract][Full Text] [Related]
13. Treatment of cardiac transthyretin amyloidosis: an update.
Emdin M; Aimo A; Rapezzi C; Fontana M; Perfetto F; Seferović PM; Barison A; Castiglione V; Vergaro G; Giannoni A; Passino C; Merlini G
Eur Heart J; 2019 Dec; 40(45):3699-3706. PubMed ID: 31111153
[TBL] [Abstract][Full Text] [Related]
14. Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis.
Maurer MS; Bokhari S; Damy T; Dorbala S; Drachman BM; Fontana M; Grogan M; Kristen AV; Lousada I; Nativi-Nicolau J; Cristina Quarta C; Rapezzi C; Ruberg FL; Witteles R; Merlini G
Circ Heart Fail; 2019 Sep; 12(9):e006075. PubMed ID: 31480867
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and Treatment of Transthyretin Cardiac Amyloidosis. Progress and Hope.
González-López E; López-Sainz Á; Garcia-Pavia P
Rev Esp Cardiol (Engl Ed); 2017 Nov; 70(11):991-1004. PubMed ID: 28870641
[TBL] [Abstract][Full Text] [Related]
16. Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis.
Griffin JM; Rosenblum H; Maurer MS
Circ Res; 2021 May; 128(10):1554-1575. PubMed ID: 33983835
[TBL] [Abstract][Full Text] [Related]
17. Sporadic Cardiac Amyloidosis by Amyloidogenic Transthyretin V122I Variant.
Nehashi T; Oikawa M; Amami K; Kanno Y; Yokokawa T; Misaka T; Yamada S; Kunii H; Nakazato K; Ishida T; Takeishi Y
Int Heart J; 2019 Nov; 60(6):1441-1443. PubMed ID: 31666456
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: a systematic review and meta-analysis.
Brownrigg J; Lorenzini M; Lumley M; Elliott P
ESC Heart Fail; 2019 Oct; 6(5):1041-1051. PubMed ID: 31487121
[TBL] [Abstract][Full Text] [Related]
19. The Ultrastructure of Tissue Damage by Amyloid Fibrils.
Koike H; Katsuno M
Molecules; 2021 Jul; 26(15):. PubMed ID: 34361762
[TBL] [Abstract][Full Text] [Related]
20. Therapy of ATTR Cardiac Amyloidosis: Current Indications.
Di Lisi D; Di Stefano V; Brighina F; Galassi AR; Novo G
Curr Probl Cardiol; 2023 Feb; 48(2):101487. PubMed ID: 36336119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
